Pleural Effusion Epidemiology Forecast 2025-2034

The incidence of pleural effusion is difficult to determine as it is generally the manifestation of an underlying disease process. In the United States, the incidence is reported to be nearly 1.5 million cases each year, with the majority of them caused by bacterial pneumonia, pulmonary embolism, congestive heart failure, and malignancy.

Pleural Effusion Epidemiology Forecast Report Coverage

The “Pleural Effusion Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of pleural effusion. It projects the future incidence and prevalence rates of pleural effusion across various populations. The study covers age and type as major determinants of the pleural effusion-affected population. The report highlights patterns in the prevalence of pleural effusion over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of pleural effusion in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Pleural Effusion: Disease Overview

In pleural effusion, excess fluid builds up in the pleural space, the area between the lungs and the chest wall. Transudative pleural effusion occurs when fluid leaks into the pleural space due to conditions like heart failure, cirrhosis, or kidney disease. Exudative effusion is typically caused by infection, inflammation, or cancer. Common symptoms include shortness of breath (dyspnea), chest pain, cough, and rapid heart rate, among others.

Pleural Effusion: Treatment Overview

The treatment for pleural effusion depends on the underlying cause of the fluid buildup. If the effusion is caused by heart failure, diuretics like furosemide are used to reduce fluid buildup in the body. Antibiotics or antitubercular drugs are prescribed in cases where an infection is responsible for pleural effusion. Thoracentesis is commonly used for diagnosis and symptom relief, especially for larger effusions. Chest tube insertion is used for severe or persistent cases to enable continuous drainage of fluid.

Epidemiology

The pleural effusion epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for pleural effusion by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for pleural effusion and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Approximately 3000 per million people worldwide are affected by pleural disease, including tuberculous PE (TPE), malignant PE (MPE), and parapneumonic effusion (PPE).
• Studies show that 150,000 new malignant pleural effusion cases are diagnosed each year, with lung and breast cancers accounting for more than 60% of malignant pleural effusions.
• The global incidence of malignant pleural effusion is estimated to be 660 per million people.
• The incidence of pleural effusion is suggested to be equal in both sexes. However, roughly two-thirds of malignant pleural effusions occur in women, typically linked to breast and gynecologic cancers.

Country-wise Pleural Effusion Epidemiology

The pleural effusion epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of pleural effusion varies significantly between countries due to differences in the prevalence of underlying diseases (such as lung cancer, pneumonia, tuberculosis, and heart failure), healthcare access, diagnostic practices, environmental factors, and lifestyle patterns. In the United States, about 1.5 million patients are affected annually by pleural effusion.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of pleural effusion based on several factors.
• The Pleural Effusion Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of pleural effusion are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of pleural effusion epidemiology in the 8 major markets?
• What will be the total number of patients with pleural effusion across the 8 major markets during the forecast period?
• What was the country-wise prevalence of pleural effusion in the 8 major markets in the historical period?
• Which country will have the highest number of pleural effusion patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of pleural effusion during the forecast period of 2025-2034?
• What are the currently available treatments for pleural effusion?
• What are the disease risks, signs, symptoms, and unmet needs of pleural effusion?

This product will be delivered within 3-5 business days.